MNTN Inc's Q1 2026: Record Revenue, BOX NOAF Trial Advances

MNTN Inc kicked off 2026 with impressive first quarter revenue, up 14.3% to $141.2 million, driven by a 14.9% growth in U.S. business to $116.2 million. Key drivers include a 29.5% jump in pain management sales and solid gains in cardiac ablation and appendage management products. The BOX NOAF clinical trial, aiming to prevent post-op atrial fibrillation, is making strides with 300 patients enrolled, ahead of schedule. Internationally, revenue grew 11.5% to $25 million, with Europe leading at 13.2% growth. MNTN is well-positioned to scale growth and profitability as they address significant unmet needs in cardiac surgery. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/6f5df386372c2fd2